A comparative assessment of neutropenia events, healthcare resource use, and costs among patients treated with long-acting granulocyte-colony stimulating factor in Germany

被引：0
|
作者：
Link, H. [1 ]
Thompson, S. F. [2 ]
Tian, M. [3 ]
Meise, D. [4 ]
Haas, J. S. [4 ]
Maas, C. [4 ]
Dimitrov, S. [5 ]
机构：
[1] Private Practice Haematol & Oncol, Haematol & Oncol, Kaiserslautern, Germany
[2] TEVA Pharmaceut, Oncol, Parsippany, NJ USA
[3] TEVA Pharmaceut, Oncol, W Chester, PA USA
[4] Xcenda GmbH, Oncol, Hannover, Germany
[5] TEVA Pharmaceut, Oncol, Amsterdam, Netherlands
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1678
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1706P
引用
收藏
页码：S1189 / S1189
页数：1
相关论文
共 48 条
  • [41] A multicenter analysis of the outcome of cancer patients with neutropenia and COVID-19 infection optionally treated with granulocyte colony-stimulating factor (G-CSF): A comparative analysis
    Sereno Moyano, M.
    Colmenarejo, G.
    Baena, J.
    Aguado de la Rosa, C.
    Mielgo, X.
    Pertejo, A.
    Alvarez, R. Alvarez
    Sanchez, A.
    Lopez, J. L.
    Molina, R.
    Lopez-Alfonso, A.
    Hernandez, B.
    Chiara Velarde, L. E.
    Martin, A. M.
    Lopez Martin, A.
    Hernandez, B.
    Chiara Velarde, L. E.
    Martin, A. M.
    Lopez Martin, A.
    Dorta Suarez, M.
    Collazo, A.
    Casado, E.
    Jimenez Gordo, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1134 - S1134
  • [42] COMPARISON OF RESOURCE USE AND COSTS IN TYPE 1 DIABETES PATIENTS TREATED WITH DIFFERENT LONG ACTING INSULINS IN A BASAL-BOLUS REGIMEN IN GERMANY
    Bierwirth, R. A.
    Kostev, K.
    Dippel, F. W.
    Fuchs, S.
    Kotowa, W.
    VALUE IN HEALTH, 2010, 13 (07) : A294 - A294
  • [43] Long-acting versus short-acting granulocyte colony-stimulating factors among cancer patients after chemotherapy in China A systematic review and meta-analysis of randomized controlled trials
    Wang, Genzhu
    Zhang, Yonghe
    Wang, Xiaoying
    Sun, Qiang
    Xun, Zhikun
    Yuan, Minglu
    Li, Zhongdong
    MEDICINE, 2021, 100 (51) : E28218
  • [44] Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor
    Dotsu, Yosuke
    Yamaguchi, Hiroyuki
    Fukuda, Minoru
    Suyama, Takayuki
    Honda, Noritaka
    Umeyama, Yasuhiro
    Taniguchi, Hirokazu
    Gyotoku, Hiroshi
    Takemoto, Shinnosuke
    Tagawa, Ryuta
    Ogata, Ryosuke
    Tomono, Hiromi
    Shimada, Midori
    Senju, Hiroaki
    Nakatomi, Katsumi
    Nagashima, Seiji
    Soda, Hiroshi
    Ikeda, Hiroaki
    Ashizawa, Kazuto
    Mukae, Hiroshi
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (18)
  • [45] COMPARING HEALTHCARE RESOURCE UTILIZATION AND COSTS AMONG SCHIZOPHRENIC PATIENTS WHO INITIATED TYPICAL VS. ATYPICAL LONG-ACTING INJECTABLES IN THE US VETERAN POPULATION
    Baser, O.
    Kariburyo, M. F.
    Du, J.
    Xie, L.
    VALUE IN HEALTH, 2015, 18 (03) : A119 - A119
  • [46] Association of primary prophylactic (PP) granulocyte-colony stimulating factor (G-CSF) use with chemotherapy dose modifications and relative dose intensity (RDI) among breast cancer patients receiving high-risk regimens for febrile neutropenia (FN)
    Shaw, Jaime
    Schenfeld, Jennifer
    Balasubramanian, Akhila
    Jaramillo, Renee
    Sandschafer, Darcie
    Kelsh, Michael Anthony
    Mahtani, Reshma L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28)
  • [47] Didanosine (ddI) ameliorates neutropenia and thrombocytopenia in patients with HIV-associated non-Hodgkin's lymphoma (NHL) treated with infusional cyclophosphamide (C), doxorubicin (D), and etoposide (E) plus granulocyte-colony stimulating factor (G-CSF).
    Sparano, JA
    Wiernik, PH
    Hu, X
    Dutcher, JP
    Sarta, C
    Henry, D
    Mason, B
    BLOOD, 1995, 86 (10) : 3724 - 3724
  • [48] The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors
    Subramanian, Janakiraman
    Fernandes, Ancilla W.
    Laliberte, Francois
    Pavilack, Melissa
    DerSarkissian, Maral
    Duh, Mei Sheng
    LUNG CANCER, 2019, 138 : 131 - 138
12345